Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients

Maria Alsina; Fernando Rivera; Francisco Javier Ramos; Maica Galán; Rafael López; Pilar García-Alfonso; José Enrique Alés-Martinez; Bernardo Queralt; Antonio Antón; Alfredo Carrato; Cristina Grávalos; Maria José Méndez-Vidal; Carlos López; Inmaculada Ruiz de Mena; Josep Tabernero; Jordi Giralt; Enrique Aranda; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and Grupo de Investigación Clínica en Oncología Radioterápica (GICOR)

doi:10.1007/s11523-017-0544-z

Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients

Target Oncol. 2018 Feb;13(1):79. doi: 10.1007/s11523-017-0544-z.

Authors

Maria Alsina¹, Fernando Rivera², Francisco Javier Ramos³, Maica Galán⁴, Rafael López⁵, Pilar García-Alfonso⁶, José Enrique Alés-Martinez^{7

8}, Bernardo Queralt⁹, Antonio Antón¹⁰, Alfredo Carrato¹¹, Cristina Grávalos¹², Maria José Méndez-Vidal¹³, Carlos López², Inmaculada Ruiz de Mena¹⁴, Josep Tabernero³, Jordi Giralt¹⁵, Enrique Aranda¹³; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and Grupo de Investigación Clínica en Oncología Radioterápica (GICOR)

Affiliations

¹ Vall d'Hebron University Hospital, Department of Medical Oncology, and Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron, 119-129, Barcelona, Spain. [email protected].
² Department of Medical Oncology, H.U. Marqués Valdecilla, Av. Valdecilla, 25 Santander, Spain.
³ Vall d'Hebron University Hospital, Department of Medical Oncology, and Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron, 119-129, Barcelona, Spain.
⁴ Department of Medical Oncology, ICO Hospitalet, Avinguda de la Granvia, 199-203, Barcelona, Spain.
⁵ Medical Oncology Department and Translational Medical Oncology Group, University Clinical Hospital and Health Research Institute (IDIS); CIBERONC, Santiago de Compostela University School of Medicine, Santiago de Compostela, Spain.
⁶ Department of Medical Oncology, H. Gregorio Marañón, Calle del Dr. Esquerdo, 46, Madrid, Spain.
⁷ Department of Medical Oncology, H. Ruber Internacional, Calle de la Masó, 38, Madrid, Spain.
⁸ Spain and H Nuestra Sra Sonsoles, C/ Avda. Juan Carlos I, Avila, Spain.
⁹ Department of Medical Oncology, H. JosepTrueta (ICO), Avinguda de França, Girona, Spain.
¹⁰ Department of Medical Oncology, H. Miguel Servet, Paseo Isabel la Católica, 1-3, Zaragoza, Spain.
¹¹ Department of Medical Oncology, H. Ramón y Cajal, Ctra. Colmenar Viejo, km. 9, 100 Madrid, Spain.
¹² Department of Medical Oncology, H. 12 de Octubre, Avenida de Córdoba, Madrid, Spain.
¹³ Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, Department of Medical Oncology, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Av. Menendez Pida, Cordoba, Spain.
¹⁴ TTD Group, Madrid, Spain.
¹⁵ Department of Radiation Oncology, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron, 119-129, Barcelona, Spain.

PMID: 29243205
DOI: 10.1007/s11523-017-0544-z

Abstract

Errors were subsequently identified in the article and the following corrections should be noted.

Publication types

Published Erratum